𝔖 Bobbio Scriptorium
✦   LIBER   ✦

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

✍ Scribed by Hauser, Stephen L.; Waubant, Emmanuelle; Arnold, Douglas L.; Vollmer, Timothy; Antel, Jack; Fox, Robert J.; Bar-Or, Amit; Panzara, Michael; Sarkar, Neena; Agarwal, Sunil; Langer-Gould, Annette; Smith, Craig H.

Book ID
118159444
Publisher
Massachusetts Medical Society
Year
2008
Tongue
English
Weight
256 KB
Volume
358
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in relapsing-remitting multipl
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
✍ Amit Bar-Or; Peter A. J. Calabresi; Douglas Arnold; Clyde Markowitz; Stuart Shaf 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

## Abstract We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted